Investigational therapies for the treatment of spinal muscular atrophy.
about
Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophyThe delivery of therapeutic oligonucleotidesPlastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy.Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.Metalloprotease-mediated cleavage of PlexinD1 and its sequestration to actin rods in the motoneuron disease spinal muscular atrophy (SMA).Treating pediatric neuromuscular disorders: The future is now.Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy.
P2860
Q28069201-EDE18829-180B-4EB0-A5DA-C4DC6E1339EDQ37210936-9ED74445-F1E6-45B0-A041-FF805CD958C9Q37677406-BB28E490-1BF2-47C0-9CB4-12AB97E6AA5CQ38718928-136E6079-C8F8-437E-9E4D-D32486DD0DDAQ47827360-F7037CC5-D416-4AD2-AB8B-B386B7AB0865Q52756417-D4A26BAA-CD44-4A5F-9BFF-5A9724203318Q55344929-05E47C3E-85ED-44FB-A33D-97897912EC15
P2860
Investigational therapies for the treatment of spinal muscular atrophy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Investigational therapies for the treatment of spinal muscular atrophy.
@en
type
label
Investigational therapies for the treatment of spinal muscular atrophy.
@en
prefLabel
Investigational therapies for the treatment of spinal muscular atrophy.
@en
P2093
P2860
P1476
Investigational therapies for the treatment of spinal muscular atrophy
@en
P2093
Anna Kaczmarek
Brunhilde Wirth
Svenja Schneider
P2860
P304
P356
10.1517/13543784.2015.1038341
P407
P577
2015-04-24T00:00:00Z